VC
CLBT icon

Voss Capital’s Cellebrite CLBT Stock Holding History

Voss Capital’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,300
Closed -$42.6K – 63
2025
Q3 		$42.6K Buy
+2,300
New +$36.1K ﹤0.01% 58

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Voss Capital's CLBT Position: Q2 2026 in Review

Voss Capital increased its Cellebrite (CLBT) stake by 18% in Q2 2026, buying an estimated $23.4M and bringing the position to 11,441,874 shares worth $167M. The position accounts for 7.76% of the portfolio, ranked #3.

Voss Capital first reported a position in CLBT in Q2 2023 and has held it in 13 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Voss Capital held 11,441,874 shares of Cellebrite worth $167M as of Q2 2026.
  • Voss Capital bought 1,766,874 Cellebrite shares in Q2 2026, an estimated $23.4M.
  • Cellebrite made up 7.76% of Voss Capital's portfolio in Q2 2026, its #3 holding.
  • Voss Capital first reported a position in Cellebrite in Q2 2023 and has held it in 13 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Voss Capital's 13F filing for Q2 2026, filed 14 Aug 2026.